... to in the content or advertisements. Parkinson’s disease rs2241703 Polymorphism SIRT2 miR-486-3p α-synuclein Parkinson’s disease (PD), one of the most common age-related neurodegenerative disorders worldwide, is pathologically characterized by the progressive loss of dopaminergic neurons within...

...Lei Zhou; Li Yang; Yu-jin Li; Rong Mei; Hua-lin Yu; Yi Gong; Ming-yue Du; Fei Wang Background/Aims: Parkinson’s disease (PD) is a frequently occurring condition that resulted from the loss of midbrain neurons, which synthesize the neurotransmitter dopamine. In this study, we established mouse...

...Junqiang Yan; Liang Qiao; Jiannan Wu; Hua Fan; Jiachun Sun; Yude Zhang Background/Aims: Many clinical studies have demonstrated that statins, especially simvastatin, can decrease the incidence of Parkinson’s disease (PD). However, the specific underlying mechanism remains unclear. This study aimed...

...Siqi Tang; Bin Yao; Na Li; Shuhuang Lin; Zunnan Huang Background/Aims: The neuropathies Alzheimer’s disease (AD), Parkinson’s disease (PD), and schizophrenia (SCZ) have different pathological mechanisms but share some common neurodegenerative features, such as gradual loss of neuronal structure...

...Jing Qu; Hongxia Yan; Yuan Zheng; Fenqin Xue; Yan Zheng; Hongjuan Fang; Yongchang Chang; Hui Yang; Jianliang Zhang Background/Aims: Alpha-synuclein (α-Syn) is a neuronal protein that is highly implicated in Parkinson’s disease (PD), and protein phosphatase 2A (PP2A) is an important serine/threonine...

... detoxifying genes. As such, Nrf2 deregulation has been linked to both aging and pathogenesis of many human chronic diseases, including neurodegenerative ones such as Parkinson’s disease, Alzheimer’s disease and amyotrophic lateral sclerosis. Nrf2 activity is tightly regulated by a fine balance between...

... neuroprotective effect and the underlying mechanism of U. rhynchophylla extract (URE) in MPP + -induced SH-SY5Y cells and MPTP-induced mice. Methods: MPP + -induced SH-SY5Y cells and MPTP-induced mice were used to established Parkinson’s disease (PD) models. Quantitative proteomics and bioinformatics were used...

... as a control, for non-motor symptoms in Parkinson’s disease (PD). Methods: PubMed, Embase and the Cochrane Library were searched from their establishment dates up to January 2017 for randomized controlled trials (RCTs) investigating the efficacy of the above ten drugs on the non-motor symptoms of PD. A network...

...Wei Xu; Deyu Zheng; Yuanyuan Liu; Ji Li; Li Yang; Xiuli Shang Background/Aims: Parkinson’s disease (PD) is a common neurodegenerative disease in the old population, characterized by dopaminergic neuron loss, inflammation and oxidative stress injury in the substantia nigra. Glaucocalyxin B (GLB...

...Yan Huang; Zhan Liu; Bei-Bei Cao; Yi-Hua Qiu; Yu-Ping Peng Background/Aims: Regulatory T (Treg) cells have been associated with neuroprotection by inhibiting microglial activation in animal models of Parkinson's disease (PD), a progressive neurodegenerative disease characterized by dopaminergic...

...Yuanyuan Liu; Shengtao Liao; Hongyu Quan; Yuhan Lin; Jian Li; Qingshan Yang Background/Aims: Development of effective therapeutic drugs for Parkinson's disease is in great need. During the progression of Parkinson's disease, Rho-associated protein kinase 2 (ROCK2) is activated to promote...

...: Cerebrospinal fluid (CSF), obtained from six Parkinson's disease (PD) patients (pre- and post-DBS) and from six normal healthy controls, was studied for differentially expressed proteins. 2-D DIGE, in combination with MALDI-TOF and TOF-TOF Mass Spectrometry (MS) or ESI-MS, was used to identify the changed...